Mean Unadjusted Change in Primary Outcome Measures From Baseline to 3-Month Follow-Up in the Living Healthy Trial
| Outcome | Baseline | Follow-Up | Raw Change in Score ± SD | P Valuea |
|---|---|---|---|---|
| WOMAC Total Score, mean ± SDb | .002 | |||
| Con | 42 ± 20 | 37 ± 19 | -5 ± 18 | |
| Int | 40 ± 20 | 30 ± 19 | -10 ± 13 | |
| Functional status subscale score, mean + SD | .01 | |||
| Con | 41 ± 22 | 36 ± 20 | -5 ± 20 | |
| Int | 39 ± 22 | 30 ± 20 | -9 ± 13 | |
| Stiffness subscale score, mean + SD | .001 | |||
| Con | 49 ± 25 | 43 ± 28 | -6 ± 25 | |
| Int | 49 ± 27 | 34 ± 26 | -15 ± 26 | |
| Pain subscale score, mean + SD | .01 | |||
| Con | 43 ± 23 | 37.9 ± 19 | -4.8 ± 21 | |
| Int | 42 ± 21 | 31 ± 21 | -10.5 ± 19 | |
| Quality of life, SF12c MCS scores, mean ± SD | .001 | |||
| Con | 38.6 ± 6.9 | 42.5 ± 7.0 | 3.8 ± 8.8 | |
| Int | 39.4 ± 6.3 | 44.2 ± 6.8 | 4.8 ± 8.8 | |
| PCS scores, mean + SD | .11 | |||
| Con | 38.1 ± 8.7 | 39.5 ± 8.4 | 1.4 ± 8.8 | |
| Int | 39.4 ± 8.9 | 40.4 ± 8.9 | 1.0 ± 9.6 | |
| Hemoglobin A,c level, %, mean ± SD | .85 | |||
| Con | 8.4 ± 2.2 | 8.4 ± 1.9 | 0.00 ± 1.3 | |
| Int | 8.2 ± 2.1 | 8.3 ± 2.0 | 0.13 ± 1.2 | |
| Systolic blood pressure, mmHg, mean + SD | .26 | |||
| Con | 133 ± 21 | 129 ± 20 | -4.5 ± 17.6 | |
| Int | 133 ± 20 | 132 ± 22 | -1.0 ± 20.0 | |
| Body mass index, kg/m2, mean ± SD | .99 | |||
| Con | 36.7 ± 7.1 | 36.8 ± 7.1 | 0.03 ± 1.3 | |
| Int | 38.3 ± 8.8 | 38.2 ± 8.7 | -0.07 ± 1.5 |
Con = control group; GEE = general estimating equation; Int = intervention group; MCS = Mental Health Component Score; PCS = Physical Component Score; SF-12 = Standard Form 12; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
↵a GEE models testing the difference in the change from baseline to follow-up between groups, adjusting for clustering and baseline values.
↵b Range 0-100; higher score indicates more pain, stiffness, and functional limitation.
↵c Range 0-100; higher score indicates greater quality of life.